If You Build It, They Will Chuckle: Northwest Bio's Super-Sized ASCO '14 Booth

My Tweeted photo of the Northwest Biotherapeutics ( NWBO) exhibition booth at the American Society of Clinical Oncology (ASCO) annual meeting doesn't do justice to its enormity.

It's huge. 


I'm sure Northwest Bio thought it would raise its profile with a booth the size of a small Illinois town, but from an investors' perspective, the company was simply the brunt of guffaws over the weekend for wasting a ridiculous amount of money. 

As expected, there was no human response data on Northwest Bio's DC-Vax Direct poster on Sunday. I did get a chance to speak with MD Anderson Dr. Vivek Subbiah about the ongoing study. I asked him if he endorsed the company's reporting of anecdotal tumor shrinkage data. With Northwest execs hovering around us, Subbiah was careful to say the only results which matter will be those reported when the DC-Vax Direct study completes. Subbiah will not be reporting data on patient tumor response while the study is underway, although the company is free to do so, he said.

Keep that in mind when you read the next on-the-fly report from the DC-Vax Direct study issued in a Northwest Bio press release


Northwest Bio shares are down 6% to $5.61 in Monday trading. 






Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K

Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K

Northwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse

Northwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse

Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash

Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data